Want to see ICCM full AI Analyst Report?
ICCM Stock Chart & Stats
$0.86
-$0.06(-4.41%)
At close: 4:00 PM EST
$0.86
-$0.06(-4.41%)
Day’s Range― - ―
52-Week Range$2.12 - $42.00
Previous CloseN/A
Volume318.06K
Average Volume (3M)6.82M
Market Cap
$10.24M
Enterprise Value$6.44M
Total Cash (Recent Filing)$8.12M
Total Debt (Recent Filing)$139.00K
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Aug 17, 2026EPS Estimate
-1.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.98
Shares Outstanding2,806,701
10 Day Avg. Volume421,789
30 Day Avg. Volume6,818,187
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)4.28
Price to Sales (P/S)11.48
P/FCF Ratio-2.65
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue1.81
Enterprise Value/Gross Profit4.94
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$44.50Price Target Upside5074.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-6
Revenue Forecast (FY)$6.37M
Bulls Say, Bears Say
Bulls Say
Regulatory & Clinical ValidationFDA marketing authorization plus an FDA‑approved 30‑site post‑market ChoICE study give durable clinical credibility. That regulatory/clinical footprint supports physician adoption, generates independent outcome data to influence guidelines and payers, and materially de-risks long-term market access.
Commercial Traction & Installed Base GrowthA rapidly expanding installed base increases recurring consumable demand and raises switching costs for customers. Persistent system placements across major U.S. centers and rising physician interest create a self-reinforcing commercial ramp that supports sustainable procedure volume growth over months to years.
Low Leverage & Positive EquityMinimal debt and a positive equity cushion reduce short‑term solvency risk and preserve financial flexibility. This conservatism allows the company to fund regulatory and commercialization activities without heavy interest burdens, lowering default risk during an extended commercialization timetable.
Bears Say
High Cash BurnSustained negative operating and free cash flow at roughly -$15.3M TTM, versus modest revenue, means internal cash generation cannot fund growth. Persistent burn forces reliance on external financing, raises dilution and execution risk, and compresses runway for scaling commercial and clinical programs.
Reimbursement UncertaintyKey physician CPT‑1 timing and conditional pass‑through status create multi‑year reimbursement timing risk. Limited or delayed physician-level coverage constrains adoption in office settings, reduces procedure economics for providers, and can materially slow conversion of interest into sustainable, high‑margin volume.
Legal & Capital Structure RisksA certified class action increases potential legal liability, management distraction and uncertainty around past financings. Coupled with recent reverse split, private placement and ongoing capital raises, this litigation and capital‑structure activity create governance and financing overhang that can hamper long‑term strategic execution.
Icecure Medical News
ICCM FAQ
What was Icecure Medical Ltd.’s price range in the past 12 months?
Icecure Medical Ltd. lowest stock price was $2.12 and its highest was $42.00 in the past 12 months.
What is Icecure Medical Ltd.’s market cap?
Icecure Medical Ltd.’s market cap is $10.24M.
When is Icecure Medical Ltd.’s upcoming earnings report date?
Icecure Medical Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 35 days.
How were Icecure Medical Ltd.’s earnings last quarter?
Icecure Medical Ltd. released its earnings results on May 12, 2026. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of -$1.4 by -$0.4.
Is Icecure Medical Ltd. overvalued?
According to Wall Street analysts Icecure Medical Ltd.’s price is currently Undervalued.
Does Icecure Medical Ltd. pay dividends?
Icecure Medical Ltd. does not currently pay dividends.
What is Icecure Medical Ltd.’s EPS estimate?
Icecure Medical Ltd.’s EPS estimate is -1.52.
How many shares outstanding does Icecure Medical Ltd. have?
Icecure Medical Ltd. has 2,806,701 shares outstanding.
What happened to Icecure Medical Ltd.’s price movement after its last earnings report?
Icecure Medical Ltd. reported an EPS of -$1.8 in its last earnings report, missing expectations of -$1.4. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Icecure Medical Ltd.?
Currently, no hedge funds are holding shares in ICCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Icecure Medical Ltd.
Headquartered in Caesarea, Israel, and founded in 2006, IceCure Medical Ltd is a medical device enterprise dedicated to inventing, refining, and marketing innovative solutions for treating human tumors through cryoablation, a freezing process. Their primary offering, the ProSense system, provides a specialized cryoablation therapy specifically for breast tumors.
ICCM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys strong positive momentum driven by 26% revenue growth, outsized North America (84%) and U.S. (31%) gains, FDA clearance, increasing active accounts (+46%), an approved 30‑site Choice post‑market study, and expanding commercial and clinical validation. Key near‑term risks include reimbursement timing (CPT‑1 and pass‑through uncertainty), limitations for office‑based reimbursement, and multi‑quarter conversion timelines for leads to system sales. On balance, the positives (regulatory milestone, accelerating sales, study approval and pipeline growth) outweigh the challenges, while some execution and reimbursement risks remain.View all ICCM earnings summariesICCM Stock 12 Month Forecast
Average Price Target
$44.50
▲(5074.42% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.44% Mutual Funds
― Other Institutional Investors
98.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---